The incidence of infection with Chlamydia trachomatis in 113 men with Reiter's syndrome was investigated. Chlamydiae were isolated from urethral specimens from 40 (39%) of 103 patients and from 36 (69%) of 52 of these men who had signs of urogenital inflammation at the time of examination. Chlamydial antibodies (titers, > or = 8) were detected in sera from 66 (63%) of 104 patients by the complement-fixation test and in sera from 79 (87%) of 91 by a single-antigen indirect immunofluorescence test. Fluorescent chlamydial antibodies were found with equal frequencies in sera from patients whose cultures were negative and sera from patients whose cultures were positive, but the geometric mean titer was higher for the latter group. The results suggest that Reiter's syndrome is frequently associated with cultural and/or serologic evidence of genital infection with C. trachomatis.

Adult↗

PubMedDate not supplied

Examination of men with nongonococcal urethritis and their sexual partners for Chlamydia trachomatis and Ureaplasma urealyticum.

Chlamydia trachomatis was recovered from 39 (52%) of 75 men who had nongonococcal urethritis and from 28 (37%) of their sexual partners. Of the partners of men with Chlamydia-positive nongonococcal urethritis, 64% excreted Chlamydia, compared with 8% of the partners of men with Chlamydia-negative nongonococcal urethritis. In contrast, an apparently sexual mode of transmission was not observed with Ureaplasma urealyticum. Rates of recovery of U. urealyticum from men with nongonococcal urethritis whose cultures were Chlamydia-positive and those whose cultures were Chlamydia-negative were the same. Significant seroconversion was detected bythe single-antigen immunofluorescence test in about 50% of patients who had Chlamydia-postive cultures.

Adult↗

PubMedDate not supplied

Rosaramicin and tetracycline treatment in Chlamydia trachomatis-positive and -negative nongonococcal urethritis.

Rosaramicin, a new macrolide antibiotic, is active in vitro against Chlamydia trachomatis and Ureaplasma urealyticum. Its efficacy in the treatment of uncomplicated nongonococcal urethritis was evaluated in 78 men. There were two parallel groups, one receiving rosaramicin and the other receiving tetracycline (dosage of either drug, 250 mg four times daily for seven days); all data were evaluated blindly. The follow-up period was six weeks. C. trachomatis was eliminated from all of 21 patients receiving rosaramicin and from 25 of 26 patients receiving tetracycline. C. trachomatis-negative patients responded clinically to both treatments. The results suggest that these two antibiotics yield similar clinical outcomes in the treatment of nongonococcal urethritis in adult men.

Chlamydia Infections↗

PubMedDate not supplied

Efficacy of interferon and placebo in the treatment of recurrent genital herpes: a double-blind trial.

One hundred patients experiencing recurrence of genital herpes were randomly assigned to treatment with either recombinant DNA-derived human leukocyte interferon (interferon alfa-2a, Roferon-A, Hoffmann-LaRoche & Co., Ltd.) or placebo in a double-blind study. All patients were given a three-day course of treatment by subcutaneous injection within 24 hr after the first signs of recurrence. Interferon alfa-2a was given according to one of two daily regimens (6 X 10(6) or 18 X 10(6) units), either as a single dose followed by two doses of placebo or as three consecutive doses. In comparison with placebo, interferon alfa-2a reduced the duration of a single recurrent episode of genital herpes by approximately 50% (P less than .05) compared with placebo. As compared with pretreatment episodes, a reduction of greater than 50% in healing time was observed in 81% of those receiving interferon alfa-2a in comparison with only 10% of placebo recipients. Response was not related to size of dose, and treatment did not significantly prolong the interval between the first and second recurrences. No serious adverse reactions were observed, but most patients developed flu-like symptoms after the subcutaneous injection. Leukopenia and thrombocytopenia were minimal and transient. On the basis of overall efficacy and adverse effects, the single dose of 6 X 10(6) units of interferon alfa-2a was considered optimal, and this regimen may be of value in the routine treatment of recurrent herpes.

Adult↗